Article: Form 8-K Bionano Genomics, Inc

Article - Media, Publications

Form 8-K Bionano Genomics, Inc/strong>

EDGARFILINGS LTD, 21 January 2021

On January 20, 2021, Bionano Genomics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Oppenheimer & Co. Inc., as representative of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering of 33,333,350 shares of the Company’s common stock, par value $0.0001 per share. The price to the public in the offering is $6.00 per share and the Underwriters have agreed to purchase the shares from the Company pursuant to the Underwriting Agreement at a price of $5.64 per share. The net proceeds to the Company from the offering are expected to be approximately $187.3 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The closing of the offering is expected to occur on January 22, 2021, subject to customary closing conditions. In addition, the Company granted the Underwriters a 30-day option to purchase up to 5,000,002 shares of the Company’s common stock at the public offering price, less the underwriting discounts and commissions. Continue reading “Article: Form 8-K Bionano Genomics, Inc”